Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 154.98M P/E - EPS this Y - Ern Qtrly Grth -
Income -29.47M Forward P/E -0.02 EPS next Y - 50D Avg Chg -
Sales 10M PEG - EPS past 5Y - 200D Avg Chg 25.00%
Dividend N/A Price/Book 2.50 EPS next 5Y - 52W High Chg -18.00%
Recommedations 1.50 Quick Ratio 6.18 Shares Outstanding 140.24M 52W Low Chg 151.00%
Insider Own 0.51% ROA -18.98% Shares Float 335.29M Beta -
Inst Own 61.41% ROE -45.56% Shares Shorted/Prior 2.19M/2.78M Price 1.24
Gross Margin 74.26% Profit Margin -294.66% Avg. Volume 1,930,119 Target Price 4.94
Oper. Margin -1,576.50% Earnings Date Mar 29 Volume 485,900 Change -8.15%
About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Mereo BioPharma Group plc News
03/27/24 Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results
03/27/24 Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
03/05/24 Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
02/16/24 Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
02/16/24 15 Top Performing European Stocks So Far in 2024
01/08/24 Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
01/08/24 Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
12/19/23 Hedge Funds Say These Penny Stocks Are Poised to Explode
11/03/23 Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
10/23/23 Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
10/14/23 Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
10/09/23 Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
09/21/23 Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
09/07/23 Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
08/10/23 BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC
08/04/23 Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
07/07/23 Ultragenyx (RARE) Doses First Patients in Bone Disease Studies
07/06/23 Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
05/31/23 Mereo BioPharma to Present at the Jefferies Healthcare Conference
05/23/23 Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
MREO Chatroom

User Image jogabonito84 Posted - 8 minutes ago

$MREO

User Image halpy518 Posted - 8 minutes ago

$MREO back into limbo we go. Cmon Denise. Get something done here.

User Image Magnificient Posted - 42 minutes ago

$MREO with Partner Minimum 9

User Image AbovetheGreenLine Posted - 3 hours ago

Swing Trade Buy today on Mereo Bio $MREO, but already up 12% today (2 Star trade). https://abovethegreenline.com/wp-content/uploads/2021/0

User Image Berakhot Posted - 5 hours ago

$MREO Cup Art...

User Image ScottyDoesntKnowMeSon Posted - 6 hours ago

$MREO white is peak volume for each shelf, green is support for each shelf, red is resistance. Rough estimates.

User Image jvj19 Posted - 6 hours ago

$IBIO $MREO All we need is volume on this stock. The stock is up 300% over the past year. 128 mil shares outstanding 128 mil shares float 1.71% short float 1.25 Short ratio 2.19 mil Short interest p/Finviz

User Image 10BillyBiggs Posted - 6 hours ago

$MREO $AKBA Sold for profits....Good luck longs ✌️

User Image BeerBubbelah Posted - 6 hours ago

$MREO How to look like a complete and utter moron

User Image Magnificient Posted - 6 hours ago

$MREO sexy

User Image RainbowTrump Posted - 6 hours ago

$MREO unmet need and they have been displaying extremely impressive results. This isn’t an AMLXl built on hopes and dreams of an a F.D.A. approval. This targets rare disease and it’s improving people’s lives

User Image Dobbins Posted - 6 hours ago

$MREO they could announce a partner at any moment. Shorts, please stay in this so you can be blown out of the water.

User Image Longroader Posted - 6 hours ago

$MREO Its a home run soon. Sit tight

User Image ScottyDoesntKnowMeSon Posted - 6 hours ago

$MREO games games games. They made you panic to get your shares. Congrats to those who stuck with and/or added. Let’s hope this holds

User Image RainbowTrump Posted - 6 hours ago

$MREO oof should have added under 3.

User Image ScottyDoesntKnowMeSon Posted - 6 hours ago

$MREO late kumu

User Image STR33 Posted - 6 hours ago

$MREO what does this mean ? the 10-k statement refer ensifentrine as a competitor and the pdufa date is related to MEREO ??

User Image Magnificient Posted - 6 hours ago

$MREO PDUFA?

User Image fda_tracker Posted - 7 hours ago

$MREO New PDUFA Date 2024-06-26 Mereo BioPharma Group plc Link:https://www.sec.gov/Archives/edgar/data/0001719714/000095017024037348/mreo-20231231.htm Calendar:http://www.fdatracker.com/fda-calendar/

User Image Quantumup Posted - 7 hours ago

Needham raised the target price on $MREO to $6 was $5/Buy, due to increasing their "launch expectations for setrusumab in OI" $rare

User Image Crivit Posted - 8 hours ago

$MREO https://x.com/ej23ny/status/1773317504770703648?s=46&t=bEBIliluVsTI7poV3L9h2Q

User Image AnaChart Posted - 9 hours ago

$MREO https://anachart.com/wp-content/uploads/ana_temp/1711623677_soc-img.jpg

User Image FK_Stocks Posted - 9 hours ago

$MREO Needham maintains Buy and raises PT to $6

User Image grod86 Posted - 23 hours ago

$MREO Give me ur expected PT when an eventual partnership is announced.

User Image halpy518 Posted - 23 hours ago

$MREO "aims to initiate the Phase 3 study with a partner around the end of 2024"

User Image Elvira007 Posted - 23 hours ago

$MREO There you go. Surprise Earnings PR dropped. If they didn't have to comply with SEC rules, who knows how long it would have taken..

User Image halpy518 Posted - 1 day ago

$MREO going all in tomorrow. They are abiut to partner and it will be a min 2B valuation when that is done. Let's gooooo

User Image Stock_Titan Posted - 1 day ago

$MREO Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update https://www.stocktitan.net/news/MREO/mereo-bio-pharma-reports-full-year-2023-financial-results-and-4hvdteprfv4s.html

User Image Elvira007 Posted - 1 day ago

$MREO This CEO is nothing short of a fucking shit show. No news. No intention of doing a better job. Fuck RUBRIC TOO. Haven't done a god damn thing since they got their 4 Board seats. Its been a fucking year plus. Even if they don't become active, WTF are the new Board members doign other than collecting free shares and sitting by while CEO moves like a fucking turtle. Get her the fuck out once and for all. The stock will go up for sure...

User Image jacobm50 Posted - 1 day ago

$MREO man, it’s going to be interesting how they manage to screw over the people still holding

Analyst Ratings
Needham Buy Mar 28, 24
Cantor Fitzgerald Overweight Mar 22, 24
Cantor Fitzgerald Overweight Sep 8, 23
Needham Buy Sep 8, 23
Needham Buy Aug 23, 23
Needham Buy Jun 6, 23
Needham Buy May 26, 23
Needham Buy Apr 21, 23
Needham Buy Mar 30, 23